EXO Therapeutics

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight platform, it develops potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. While roughly 10,000 proteins are involved in human disease, only about 700 are currently accessible as pharmaceutical targets; Exo aims to expand that druggable universe. Its scientific approach is based on research from the labs of Drs. David Liu and Alan Saghetelian following their discovery of non-active site inhibitors that selectively reprogram Insulin Degrading Enzyme, unlocking breakthrough therapeutics in oncology, inflammation, and other diseases.